Technical Analysis for BLUE - bluebird bio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Inside Day | Range Contraction | 0.00% | |
| BB Squeeze Ended | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 4.90% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 4.90% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 12 hours ago |
| 60 Minute Opening Range Breakdown | about 15 hours ago |
| Reversed from Up | about 15 hours ago |
| Gap Up Closed | about 16 hours ago |
| Gap Up Partially Closed | about 16 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 06/14/2024
bluebird bio, Inc. Description
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on the development, manufacture, and marketing of therapies to treat various human diseases. Its product candidates include Lenti-D to treat patients with childhood cerebral adrenoleukodystrophy (ALD), a hereditary neurological disorder, as well as for the treatment of adult cerebral ALD; and CAR T cells products for treating oncology diseases. The company's product candidates also comprise LentiGlobin vector for the treatment of ß-thalassemia, a hereditary blood disorder; and sickle cell diseases. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Rare Diseases Medical Genetics Dystrophy Human Diseases Summit Childhood Genetic Genealogy Sickle Cell Disease Thalassemia Iglo Oncology Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.53 |
| 52 Week Low | 0.851 |
| Average Volume | 7,234,893 |
| 200-Day Moving Average | 2.27 |
| 50-Day Moving Average | 1.16 |
| 20-Day Moving Average | 0.98 |
| 10-Day Moving Average | 1.01 |
| Average True Range | 0.11 |
| RSI (14) | 52.38 |
| ADX | 19.53 |
| +DI | 21.42 |
| -DI | 12.09 |
| Chandelier Exit (Long, 3 ATRs) | 0.90 |
| Chandelier Exit (Short, 3 ATRs) | 1.18 |
| Upper Bollinger Bands | 1.11 |
| Lower Bollinger Band | 0.84 |
| Percent B (%b) | 0.86 |
| BandWidth | 27.22 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.05 |
| MACD Histogram | 0.0281 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.19 | ||||
| Resistance 3 (R3) | 1.20 | 1.17 | 1.17 | ||
| Resistance 2 (R2) | 1.17 | 1.14 | 1.17 | 1.16 | |
| Resistance 1 (R1) | 1.12 | 1.12 | 1.11 | 1.11 | 1.16 |
| Pivot Point | 1.09 | 1.09 | 1.08 | 1.09 | 1.09 |
| Support 1 (S1) | 1.04 | 1.06 | 1.03 | 1.03 | 0.98 |
| Support 2 (S2) | 1.01 | 1.04 | 1.01 | 0.98 | |
| Support 3 (S3) | 0.96 | 1.01 | 0.97 | ||
| Support 4 (S4) | 0.95 |
